Cristian Ionescu-Zanetti, PhD
Co-founder and CTO
Low signal-to-noise samples such as cfDNA-based liquid biopsies require improvements in sensitivity and specificity to provide the level of performance required for clinical utility. A common solution is the use of unique molecular identifiers (UMIs) to track individual molecules being amplified, but UMIs have their own limitations when used with real-world blood samples with low DNA inputs.
This webinar will introduce ERASE-Seq, a novel approach to accurate calling for ultra-low MAF variants that does not require the use of UMIs. The webinar will cover the following topics:
The cfDNA analytical challenge- how low do we need to go to achieve traditional biopsy sensitivity?
Sources of error in liquid biopsy variant calling
Approaches to ultra-low MAF detection - LoFreq, UMIs, etc.
ERASE-Seq variant calling using Molecular Amplification Pools (MAPs) without UMIs
Adaption of ERASE-Seq to existing and custom panels
How to access and run the ERASE-Seq caller application via a free trial
The following case studies will be presented:
Applying ERASE-Seq to existing datasets
Implementing ERASE-Seq with or without MAPs to an existing panel
Applying ERASE-Seq to existing pre-validated NGS panels
Development and validation of a new NGS panel
Interested in learning more about IsoFlux, Spotlight 59, or ERASE-Seq? Stop by the booth or contact firstname.lastname@example.org to set up a meeting. We will also present two exciting posters on ultra-sensitive liquid biopsy NGS with collaborators from LSU Health Center and Clinical Hospital Lyon.